NCT02979340 is a clinical trial of MRI in Cystic Fibrosis Liver Disease, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Who is sponsoring NCT02979340?

NCT02979340 is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

What drugs are being tested in NCT02979340?

Interventions in NCT02979340: MRI.

What condition does NCT02979340 study?

NCT02979340 studies Cystic Fibrosis Liver Disease, Pancreatic Insufficiency.

Is NCT02979340 still recruiting?

NCT02979340 is currently completed. Last updated 11 April 2025.

Last reviewed 2025-04-11 · How we verify

NCT02979340

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MRI to Characterize and Predict CF Liver Disease in PUSH Cohort

Completed Last updated 11 April 2025

What this trial tests

trial testing MRI in Cystic Fibrosis Liver Disease in 115 participants. Completed in 27 December 2019.

Timeline

27 January 2017

Primary endpoint
27 December 2019

27 December 2019

Quick facts

Lead sponsor	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	115
Start date	27 January 2017
Primary completion	27 December 2019
Estimated completion	27 December 2019
Sites	8 locations across United States

Drugs / interventions tested

MRI — full drug profile →

Conditions studied

Cystic Fibrosis Liver Disease — all drugs for Cystic Fibrosis Liver Disease →
Pancreatic Insufficiency — all drugs for Pancreatic Insufficiency →

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Who can join

Adults 6 to 26, any sex, with Cystic Fibrosis Liver Disease or Pancreatic Insufficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Specific Aim 1. Determine if valid results of non-sedated MRI based assessments of liver stiffness and lipid content can be obtained in more than 90% of children and young adults with cystic fibrosis. Specific Aim 2. Determine hepatic lipid content using the HepaFat sequence and liver stiffness using MRE. Investigators will compare the results obtained by MRI with PUSH study grayscale ultrasounds in CF patients with normal, heterogeneous, homogeneous or nodular (cirrhotic) pattern on ultrasound. Specific Aim 3. Creation of an imaging core lab to centralize evaluation of MR imaging data, allow for remote image upload, electronic data storage, and remote image viewing/interpretation. This infrastructure will be utilized to standardize image post processing. Specific Aim 4. Using the longitudinal PUSH study, determine if MRI based imaging improves discrimination of subjects at risk for progression to advanced CF liver disease (development of cirrhosis) compared to using US imaging alone

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Prospective study of quantitative liver MRI in cystic fibrosis: feasibility and comparison to PUSH cohort ultrasound.
Towbin AJ, Ye W, Huang S, Karmazyn BW, et al · · 2023 · cited 3× · PMID 37500799 · DOI 10.1007/s00247-023-05706-6

Verify or expand the search:

Other trials of MRI

Trials testing the same drug.

NCT02831335 — Technical Development of Multi-Parametric Renocerebral MRI · recruiting
NCT07487870 — Radiographic Evaluation of Tumor Biology During Neoadjuvant Radiotherapy for Sarcoma · NA · not yet recruiting
NCT07567053 — Repetitive Transcranial Magnetic Stimulation on Motor Function and Meta-Plasticity in Cerebral Palsy: TMS-EEG Study · NA · not yet recruiting
NCT07537504 — Language Function Reorganization in Patients With Arteriovenous Malformations · not yet recruiting
NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Cystic Fibrosis Liver Disease

Currently open trials in the same condition.

NCT04602468 — Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) · Phase 4 · active not recruiting

Other National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) trials

Trials by the same sponsor.

NCT07313787 — Effects of Meal Macronutrients on Postprandial Lipids · Phase 2 · not yet recruiting
NCT07388537 — Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults · not yet recruiting
NCT05713799 — Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity · Phase 2 · not yet recruiting
NCT05722210 — Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant · not yet recruiting
NCT07191561 — Hepatic Lipid Metabolism-Alcohol Use Disorder · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02979340 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Last refreshed: 11 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02979340.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing